Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count.
Adjusting platelet count (PC) in platelet-rich plasma (PRP) using platelet-poor plasma (PPP) is recommended for platelet aggregation (PA) studies, but it could also affect PA independently of the decrease in PC. Analysis of aggregation tracings from healthy controls showed that PC correlated with PA in 47 diluted-PRPs, but not in 104 undiluted-PRPs. Dilution of 9 PRPs with PPP progressively decreased PA, while dilution of washed platelets with buffer hardly affected PA. Apyrase partially prevented the inhibitory effect of PPP. Therefore, the practice of diluting PRP with PPP to adjust platelet count should be avoided because it artefactually inhibits PA.
Cattaneo
Marco
M
Unità di Ematologia e Trombosi, Ospedale San Paolo, DMCO Università di Milan, Milan, Italy. marco.cattaneo@unimi.it
Lecchi
Anna
A
Zighetti
Maddalena Loredana
ML
Lussana
Federico
F
D000244:Adenosine Diphosphate / Q000097:blood / Q000494:pharmacology; D001081:Apyrase / Q000494:pharmacology; D016477:Artifacts; D002021:Buffers; D002498:Centrifugation; D003094:Collagen / Q000494:pharmacology; D006801:Humans; D009391:Nephelometry and Turbidimetry; D010949:Plasma; D010972:Platelet Activating Factor / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count; D010979:Platelet Function Tests; D053657:Platelet-Rich Plasma
D002021:Buffers; D010972:Platelet Activating Factor; D000244:Adenosine Diphosphate; D003094:Collagen; D001081:Apyrase